Psychotic Depression
RECors Trial
A Research Study of the Reduction of the Effects of Cortisol in Psychotic Depression
High levels of cortisol in the body can play a role in a variety of diseases and disorders. Scientific literature suggests that high levels of cortisol have the potential to cause the psychotic symptoms associated with psychotic depression. Because mifepristone blocks the effects of cortisol, it is being studied as a potential treatment for psychotic depression. The goal of this phase 3 trial is to evaluate whether the use of mifepristone can decrease the psychotic symptoms, and to assess the safety of mifepristone in patients with psychotic depression.
Enrollment at sites across the United States is currently open to qualifying patients. To learn more about the RECors Trial, including objectives, enrollment criteria, eligibility, and site locations, visit RECorsTrial.com or ClinicalTrials.gov.